Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Balanced Outlook on ResMed: Strong Execution and Innovations Offset by Valuation Concerns and Market Challenges
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...